Peer-reviewed veterinary case report
Liposome-DNA infusions reduce tumor blood vessels in dogs with soft
By Kamstock, D et al.·Published in Cancer gene therapy·2006·Department of Microbiology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma.
- Species:
- dog
Plain-English summary
A group of 13 dogs with soft tissue sarcomas (a type of cancer) received six weekly intravenous treatments with a special gene therapy using liposome-DNA complexes. While the therapy did not show clear gene expression in the tumors, two dogs had noticeable tumor shrinkage, and eight dogs maintained stable disease during treatment. Additionally, six dogs showed a significant reduction in blood vessel growth within their tumors after the treatment. This suggests that the therapy may help slow tumor growth and reduce blood supply, although more research is needed to understand its effectiveness fully.
People also search for: dog soft tissue sarcoma treatment · gene therapy for dogs · canine cancer blood vessel growth
Abstract
Intravenous gene delivery using liposome-DNA complexes (LDC) has previously been shown to elicit antitumor activity, but only in rodent tumor models. Therefore, we conducted a study to determine in a large animal spontaneous tumor model whether intravenous infusions of LDC could target gene expression to cutaneous tumor tissues and whether repeated treatments had an effect on tumor growth or angiogenesis. A total of 13 dogs with cutaneous soft tissue sarcomas were enrolled in the study and were randomized to receive a series of 6 weekly infusions of LDC containing either canine endostatin DNA or DNA encoding an irrelevant gene (luciferase). Serial tumor biopsies were obtained to assess transgene expression, tumor microvessel density (MVD), and intratumoral leukocyte inflammatory responses. We found that intravenous infusion of LDC did not result in detectable gene expression in cutaneous tumor tissues. However, two of 13 treated dogs had objective tumor responses and eight dogs had stable disease during the treatment period. In addition, a significant decrease in tumor MVD was noted in six of 12 treated dogs at the completion of six treatments. These results suggest that intravenous infusions of LDC may elicit nonspecific antitumor activity and inhibit tumor angiogenesis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16138118/